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Contributed by Johannes J. van Rood, May 6, 2010 (sent for review December 16, 2009) Adoptive transfer of T cell receptor (TCR)-transduced T cells may be an attractive strategy to target both hematological malignancies and solid tumors. By introducing a TCR, large numbers of T cells with defined antigen (Ag) specificity can be obtained. However, by introduction of a TCR, mixed TCR dimers can be formed. Besides the decrease in TCR expression of the introduced and endogenous TCR, these mixed TCR dimers could harbor potentially harmful specificities. In this study, we demonstrate that introduction of TCRs resulted in formation of neoreactive mixed TCR dimers, composed of the introduced TCR chains pairing with either the endogenous TCR α or β chain. Neoreactivities observed were HLA class I or class II restricted. Most neoreactive mixed TCR dimers were allo-HLA reactive; however, neoreactive mixed TCR dimers with autoreactive activity were also observed. We demonstrate that inclusion of an extra disulfide bond between the constant domains of the introduced TCR markedly reduced neoreactivity, whereas enhanced effectiveness of the introduced TCR was observed. In conclusion, TCR transfer results in the formation of neoreactive mixed TCR dimers with the potential to generate offtarget effects, underlining the importance of searching for techniques to facilitate preferential pairing.
gene transfer | adoptive immunotherapy | mispairing A doptive transfer of T cells is a strategy used to target both solid tumors and leukemia. Patients with relapsed hematological malignancies after allogeneic stem cell transplantation can be successfully treated with donor lymphocyte infusion (DLI) (1, 2) , and patients with solid tumors can be effectively treated with tumor-infiltrating lymphocytes (TILs) cultured from tumor tissue (3) . The beneficial graft-versus-leukemia effect of DLI mediated by the recognition of minor histocompatibility antigens (mHags) is, however, often accompanied by graft-versushost disease. Furthermore, isolation and expansion of TILs is feasible only for a fraction of patients with solid tumors. The adoptive transfer of T cells transduced with T cell receptors (TCRs) recognizing tumor-associated antigens or mHags may be an attractive alternative strategy to target hematological malignancies and solid tumors. By introducing a TCR, large numbers of T cells with defined antigen (Ag) specificity can be obtained without long in vitro culture periods. Different studies have shown the effectiveness of TCR transfer, both in vitro (4) (5) (6) (7) (8) and in vivo (9) (10) (11) . Recently, the in vivo efficacy of adoptively transferred TCR transduced (td) T cells was demonstrated in melanoma patients (10, 12) .
The introduction of an exogenous TCR into T cells has several consequences for the TCR make-up of the cell. The introduced TCR has to compete for cell surface expression with the endogenous TCR, and with mixed TCR dimers consisting of an endogenous TCR chain pairing with an introduced TCR chain (13) . Because of competition of these different TCR complexes for binding with CD3, the frequency of TCRs at the cell surface will be lower in TCR td T cells than in parental T cells. Therefore, a prerequisite of the introduced TCR is that it exhibits high affinity for its antigen, and is able to efficiently compete with the endogenous TCR for cell surface expression (13) . Different studies have attempted to improve TCR surface expression and subsequently biological activity, by facilitating matched pairing of the introduced TCR chains. Exchange of the human constant regions for murine constant regions was described to improve TCR expression and functionality (14, 15) . Another strategy that resulted in preferential pairing of the introduced TCR chains and increased TCR surface expression is the introduction of a disulfide bond in the extracellular constant domain (16, 17) .
Not only the decrease in TCR expression of the introduced Agspecific TCR, but also the formation of mixed TCR dimers with unknown specificity is an additional potential drawback of clinical application of TCR gene transfer (13, 18, 19) . Because the specificity of mixed TCR dimers is unpredictable, hazardous specificities may be formed. In this study, we investigated whether TCR transfer can lead to the generation of mixed TCR dimers exhibiting new detrimental reactivities. To address this issue, we created T cells expressing mixed TCR dimers. To be able to discriminate between the functionality of the endogenous TCR, the introduced TCR, as well as mixed TCR dimers, we transduced different defined virus-specific T cells with seven different well characterized Ag-specific TCRs and tested these for newly acquired reactivities against an HLA-typed LCL panel covering all prevalent HLA class I and II molecules. Our results demonstrate that pairing of endogenous TCR chains with introduced TCR chains can result in the formation of mixed TCR dimers with new, potentially hazardous specificities recognizing allo-antigens as well as auto-antigens, both HLA class I and class II restricted.
Results

Introduction of Different TCRs into Several Virus-Specific T Cells Elicits
Neoreactivity Mediated via Mixed TCR Dimers. To study whether TCR transfer can lead to mixed TCR dimers with new detrimental reactivities, we transduced various virus-specific T cell lines from four healthy donors with different Ag-specific TCRs. HLA-A1 restricted pp50-or pp65-specific T cells and HLA-B8 restricted IE-1-or BZLF-1-specific T cells were sorted, resulting in five different virus-specific T cell lines (Table S1 ). These T cell lines were transduced with 7 different TCRs, consisting of four different HA-2-specific TCRs (HA2.5-TCR, HA2.6-TCR, HA2.19-TCR, and HA.2.20-TCR), two different HA-1-specific TCRs (HA1.M2-TCR and HA1.M7-TCR), and the CMV-TCR. The transduced virus-specific T cells were sorted based on high eGPF and NGF-R positivity, and tested for neoreactivity against the LCL panel (Table S2 ) covering all prevalent HLA class I and class II molecules. Introduction of different TCRs resulted in newly acquired reactivities against different LCLs, of which representative examples are shown in Fig. 1 . Some LCLs were excluded from analysis, as the non-td virus-specific T cells already recognized the LCLs, indicative for alloreactivity of the virus-specific T cells rather than neoreactivity via mixed TCR dimers (Table S1 ). We could exclude alloreactivity of the introduced TCRs, as the parental T cell clones of which these TCRs were derived were not reactive against the LCLs present in the panel. In each of the five different virus-specific T cell lines, transfer of at least two of seven TCRs induced neoreactivity (Table S1 ). As illustrated in Fig. 1A , pp50-specific T cells of healthy individual CVO (CVO pp50 T cells) transferred with the CMV-TCR exhibited strong reactivity particularly against ZIL. This reactivity was not seen with HA2.6-TCR td or HA1.M7-TCR td CVO pp50 T cells. HA1.M7-TCR transfer resulted in strong reactivity directed against LSR, which was not observed with HA2.6-TCR td or CMV-TCR td CVO pp50 T cells. Introduction of the HA2.6-TCR into pp50-specific T cells of healthy individual UKL (UKL pp50 T cells) resulted in clear neoreactivity (Fig. 1B) , whereas low neoreactivity was observed after introduction of the HA1.M7-TCR or the CMV-TCR into these T cells. Introduction of the HA2.6-TCR and HA1.M7-TCR into IE-1-specific T cells of healthy individual MBX (MBX IE-1 T cells) resulted in neoreactivity against different LCLs (Fig. 1C) . Strikingly, some neoreactivities were as robust as reactivity via the introduced or endogenous TCR against peptide pulsed target cells. To determine whether the observed neoreactivities against LSR after HA1.M7-TCR transfer and against ZIL after CMV-TCR transfer (Fig. 1A) were mediated via mixed TCR dimers, we transduced CVO pp50 T cells with either the HA1.M7-TCR α or β chain ( Fig. 2A) , or either the CMV-TCR α or β chain (Fig. 2B) . Transduction of only the HA1.M7-TCR β and not α chain ( Fig.  2A ) resulted in neoreactivity directed against LSR. Transduction of only the CMV-TCR α chain and not β chain (Fig. 2B) into these T cells resulted in neoreactivity directed against ZIL. In addition, to test whether the observed neoreactivities of MBX IE-1 T cells after HA2.6-TCR transfer (Fig. 1C) were mediated via mixed TCR dimers, we transduced these T cells with either only the HA2.6-TCR α or β chain. As shown in Fig. 2C , only HA-2.6-TCRβ td T cells demonstrated neoreactivity directed against IZA. Furthermore, we deliberately created mixed TCR dimers by recombining HA-2-specific TCRα and TCRβ chains of four different HA-2-TCRs, namely the HA2.5-TCR, the HA2.6-TCR, the HA2.19-TCR and the HA2.20-TCR and transducing all possible combinations into monoclonal CVO pp50 T cells. Taking into account that also the introduced HA-2-TCR chains can pair with the endogenous TCR of the pp50 T cells, this resulted in potentially 20 mixed TCR dimers. Of these 20 mixed TCR dimers, the recombination of HA2.19-TCRα and HA2.6-TCRβ chain ( Fig. S1A ; mixed TCR dimer) resulted in significant IFN-γ production against DMD, whereas the parental HA2.19-TCR and HA2.6-TCR demonstrated only HA-2-specific reactivity against HA-2 peptide pulsed target cells. These results indicate that each recombination of TCR chains after TCR transfer can potentially result in a harmful new reactivity.
These results demonstrate that neoreactivities can occur in multiple virus-specific T cells after transfer of different TCRs. The neoreactive mixed TCR dimers can be composed of introduced TCR chains pairing with either the endogenous TCRα chain or the endogenous TCRβ chain. LSR expressed HLA-B35, B52 and Cw12. Additional experiments using various LCLs expressing one of these HLA restriction molecules demonstrated that this neoreactivity was HLA-B52 mediated (Fig. 3A) . In addition, the neoreactivity of CMV-TCRα td BV1 + CVO pp50 T cells against ZIL (Figs. 1A and 2B) was also HLA-B or HLA-C restricted, as the reactivity could be blocked with HLA class I and HLA-B/C antibodies (Fig. 3B) . ZIL expressed HLA-B56, B58, and Cw1, and additional testing against LCLs covering these different HLA restriction molecules demonstrated this neoreactivity to be HLA-B58 restricted (Fig. 3B) . The neoreactivity of the HA2.6-TCRβ td MBX IE-1 T cells (Figs. 1C and 2C ) was demonstrated to be HLA-DR17 restricted, based on blocking with HLA class II and HLA DR mAbs and testing with an additional LCL panel (Fig. 3C) . The neoreactivity of the HA2.19-TCRα and HA2.6-TCRβ mixed TCR dimer could be blocked with HLA class II and HLA-DQ mAbs, and testing on an additional LCL panel demonstrated that this neoreactivity was HLA-DQ3(8/9) restricted (Fig. S1B ).
In conclusion, mixed TCR dimers derived from HLA class Irestricted T cells can acquire neoreactivities that can be both HLA class I and HLA class II restricted. In Fig. 3C , we demonstrate that the HA2.6-TCRβ chain, in combination with the TCRα chain of the endogenous TCR from MBX IE-1 T cells, resulted in a HLA-DR17 restricted neoreactivity. Because MBX was also HLA-DR17 positive, we tested these neoreactive T cells for recognition of autologous LCLs derived from MBX. Mixed TCR dimers produced IFN-γ (Fig. S2A ) and were cytolytic (Fig.  S2B ) against HLA-DR17 + LCLs including MBX, and reactivity against all LCLs could be blocked using HLA class II and HLA-DR mAbs (Fig. S2C) . These results indicate that mixed TCR dimers may lead not only to newly acquired alloreactivity but also to autoreactivity. (Figs. 4 B and C and S3B ). The HLA-B58 restricted neoreactive T cells were able to recognize all different cell subsets directly ex vivo (Fig. 4A) . The HLA-DR17 restricted neoreactive T cells did not recognize the cell subsets directly ex vivo but recognized the autologous activated CD19 + and CD14 + cell subsets of MBX as well as the allogeneic activated CD19 + , CD14 + , and CD4 + cell subsets of NGI (Fig. 4  B and C) . The absence of IFN-γ production against autologous activated CD4 + T cells derived from MBX was not surprising, as no signs of self-reactivity of the HA2.6-TCRβ td MBX IE-1 T cells were observed, and these T cells could be easily expanded using feeder cells and PHA. Cytolytic capacity of CMV-TCRα td CVO pp50 T cells (Fig. S3A ) corresponded with the IFN-γ production against these cell subsets (Fig. 4A) . The HA2.6-TCRβ td MBX IE-1 T cells, however, exerted cytolytic activity against nonactivated CD19 + and allogeneic CD4 + cell subsets derived from NGI, whereas no IFN-γ production was observed after stimulation with these cell subsets, indicating that the threshold for cytolytic activity is easier reached than the threshold for cytokine production. The T cells did not exert cytolytic activity against the nonactivated autologous cell subsets from MBX (Fig. S3B ) corresponding with the IFN-γ production (Fig. 4B ). These results demonstrate that the observed neoreactivities against the LCL panel are predictive for reactivity against normal human cell subsets.
In conclusion, T cells expressing neoreactive mixed TCR dimers can recognize normal cell subsets, and are capable of both producing cytokines and demonstrating cytolytic activity.
Transfer of Cysteine-Modified TCRs Reduces Neoreactivity. To determine whether strategies facilitating matched pairing could reduce potentially harmful neoreactivities, we modified the HA1. M7-TCR by inclusion of extra cysteine residues in the constant domains of the TCR chains. UKL BZLF-1 T cells that exhibited HLA-DR4 restricted neoreactivity after transduction with the HA1.M7-TCR (Fig. S4 ) were either transduced with retroviral vectors encoding the unmodified HA1.M7-TCR α and β chains (HA1.M7-TCR WT) or with cysteine modified HA1.M7-TCR α and β chains (HA1.M7-TCR SS), sorted on bases of high eGFP and ΔNGF-R expression and tested against the LCL panel for neoreactivity. Whereas the HA1.M7-TCR WT td T cells exhibited neoreactivity against the HLA-DR4 + EBM, the HA1. M7-TCR SS td T cells showed limited neoreactivity (Fig. 5A) . In contrast to reduced neoreactivity, the HA1.M7-TCR SS td T cells exhibited increased HA-1-specificity (Fig. 5A ). In addition, we studied whether HLA-B52 restricted neoreactivity of HA1.
M7-TCR td BV1
+ CVO pp50 T cells (Figs. 1A, 2A , and 3A) could be reduced by inclusion of cysteine residues in the HA1. M7-TCR. CVO pp50 T cells were transduced with retroviral vectors encoding both the HA-1-TCR α and β chain linked with a self-cleaving 2A sequence (T2A) that were either unmodified (HA1.M7-TCR T2A WT) or cysteine modified (HA1.M7-TCR T2A SS), sorted on bases of high ΔNGF-R expression, and tested against the LCL panel for neoreactivity. As can be observed in Fig. 5B , CVO pp50 T cells transduced with the HA1. M7-TCR T2A WT demonstrated neoreactivity directed against HLA-B52 + LSR and SAV. However, also this HLA-B52 restricted neoreactivity was markedly reduced by cysteine modification of the HA1.M7-TCR (Fig. 5B) , whereas the reactivity against HA-1 + target cells increased. The results indicate that inclusion of an additional disulfide bond between the introduced TCR chains markedly decreased neoreactivity and, in addition, increased the effectiveness of the introduced TCRs.
Discussion
In this study, we investigated whether TCR gene transfer can lead to the generation of new detrimental reactivities by creating T cells that express mixed TCR dimers. For this purpose, we introduced seven different TCRs into five virus-specific T cell populations derived from healthy donors, and tested these transduced T cell populations against an LCL panel covering the most prevalent HLA class I and II molecules. Per virus-specific T cell line, at least two of seven TCR-transductants demonstrated neoreactivities. We could demonstrate that introduction of only TCR α or β chains resulted in neoreactivity, and that this neoreactivity could be HLA class I or class II mediated. Furthermore, we observed neoreactive mixed TCR dimers harboring not only alloreactivity but also autoreactivity. Therefore, we conclude that mixed TCR dimers formed will frequently harbor new, potentially harmful specificities.
Relatively high frequencies of neoreactive mixed TCR dimers were found. Normally, during development, T cells undergo thymic selection, resulting in a T cell repertoire consisting of T cells capable of binding to self-peptide-self-MHC complexes with adequate affinity. Potentially autoimmune T cells that have high affinity for self-peptide-self-MHC complexes are deleted. Alloreactivity refers to the ability of T cells to recognize peptideallogeneic-MHC complexes that were not encountered during thymic development, and we have recently described that alloreactivity by virus-specific T cells is frequently observed (20) . In the case of the mixed TCR dimers, no thymic selection has occurred at all, and by chance both allo-and autoreactive mixed TCR dimers can be engineered. TCR td T cells harboring autoreactive mixed TCR dimers will be able to survive only when the peptide recognized is not expressed on the T cells themselves, as this may lead to fratricide of these T cells.
In our model, we measured T cell reactivity against a LCL panel covering a large spectrum of different HLA molecules expressing different peptides. Theoretically, by using this model, it is more likely that we will pick up neoreactive mixed TCR dimers recognizing either a peptide in the context of allo-HLA than in the context of self-HLA, as a maximum of 12 self-HLA alleles will be shared with the LCLs in the panel, whereas up to 77 HLA molecules will be foreign to the T cells. However, we also identified a neoreactive mixed TCR dimer recognizing peptides bound to self-HLA, namely the HLA-DR17-reactive HA2.6-TCRβ td MBX IE-1 T cells. These self-reactive T cells were capable of recognizing only autologous DCs and activated B cells, and not activated autologous CD4 + T cells, whereas both activated and resting allogeneic cell subsets (NGI) were recognized. This lack of reactivity against activated autologous CD4 + T cells was not surprising, as these HLA-DR17-neoreactive MBX IE-1 T cells could be easily expanded using feeder cells and PHA. Furthermore, NGI-derived target cells were always better recognized (Fig. 4 B and C and Figs. S2 and S3) , indicating that the target antigen might be expressed more highly in NGI-derived CD4 + T cells compared with MBX-derived CD4 + T cells. In addition, HLA-DR expression on activated T cells is lower than on LCLs and DCs, and, in combination with lower antigen expression on MBX-derived target cells, possibly the threshold for activation of the autoreactive T cells by MBX-derived CD4 + T cells is not reached. We cannot conclude from these data whether the mixed TCR dimers recognize different antigens expressed by MBX and NGI, although IFN-γ production against both LCL MBX and LCL NGI could be blocked using HLA class II-and HLA-DR-blocking mAbs, or whether they recognize possibly differentially expressed antigens by these two LCLs.
In a pp50-specific T cell clone, we observed neoreactivity in three of seven TCR transductions. Theoretically, the introduction of seven TCRs into a monoclonal virus-specific T cell population will result in 14 mixed TCR dimers. Of these 14 mixed TCR dimers, three were demonstrated to be neoreactive, indicating that approximately one of five mixed TCR dimers will harbor a new specificity. Furthermore, deliberately creating mixed TCR dimers by recombining four different HA-2-TCRs into a BV1 + CVO pp50 T cell clone resulted in one neoreactive mixed TCR dimer out of 20. On average, we conclude that approximately one of 10 mixed TCR dimers will harbor potentially hazardous neoreactivity. The results demonstrate that selecting strong competitor TCRs could not avoid occurrence of neoreactive mixed TCR dimers, as has been proposed previously as a strategy to acquire single TCR expression on transduced T cells (21) . For example, introduction of a strong competitor CMV-TCR into weak competitor pp50-specific T cells resulted in HLA-B58-restricted neoreactive mixed TCR dimers. Also, the introduction of a strong competitor HA2.6-TCR into strong competitor IE1-specific T cells resulted in HLA-DR17-restricted neoreactive mixed TCR dimers. These results imply that TCR transfer will frequently result in the formation of neoreactive mixed TCR dimers.
To date, however, no off-target toxicity has been observed in clinical trials treating in total 51 patients with either MART-1-TCR td or gp100-TCR td T cells (10, 12) . Although no evidence of mixed TCR dimer-induced autoimmunity was observed in earlier murine experiments or these first clinical trials, in a recent set of experiments an often lethal autoimmune pathology was observed under conditions that promote the expansion of adoptively transferred T cells more strongly, and this pathology appeared to be dependent on the action of mixed TCR dimers (22) .
There are different techniques described that facilitate matched pairing of the introduced TCR chains. Exchange of the human constant regions for murine constant regions was described to improve TCR expression and functionality (14, 15) . However, murine constant regions can be potentially immunogenic in vivo. Another strategy that facilitated matched pairing and increased TCR surface expression is the introduction of an extra disulfide bond in the constant domains of the introduced TCR chains (16, 17) . In this study, we demonstrate that cysteine modification of the potentially clinical useful HA1.M7-TCR considerably reduced the neoreactivity of two TCR td virusspecific T cell populations tested. Potentially, the stochiometric production of TCR α and β chains, when linked with a selfcleaving 2A peptide (23) , could also result in increased preferential pairing of the TCR chains and lower expression of mixed TCR dimers. However, CVO pp50 T cells transduced with HA1. M7-TCR chains linked with a T2A sequence still demonstrated marked neoreactivity (Fig. 5B) , indicating that stochastic expression of the TCR α and β chain does not rule out the generation of mixed TCR dimers. Next to decreased neoreactivity using cysteine modified TCRs, increased HA-1 specificity was observed, making the cysteine-modified HA-1.M7-TCR more attractive than the unmodified HA1.M7-TCR for future clinical trails. Whether the results obtained with the cysteine-modified HA1.M7-TCR are predictive for other TCRs potentially useful for clinical therapy has yet to be tested.
To completely rule out formation of harmful mixed TCR dimers, another option would be to transduce γδ-T cells, as the γδ-TCR chains are not able to pair with αβ-TCR chains (19) . Human γδ-T cells redirected with αβ-TCRs were fully functional in vitro (19) and in vivo (24) . However, further analyses will be required to determine to what extent redirected γδ-T cells and αβ-T cells are different with respect to homing properties and specificity of the endogenous TCR. We therefore propose to limit the diversity of the TCR repertoire of the recipient T cells by transducing virus-specific T cell populations. Because virusspecific T cell populations consist of a restricted TCR repertoire (25, 26) , the amount of different mixed TCR dimers formed will be limited. In addition, the reactivity of these T cells is known, allowing detection of harmful neoreactivities by introducing into these virus-specific T cells as controls only the TCRα or TCRβ chain of interest and subsequent testing against different patientderived cell types. By this procedure, TCR td virus-specific T cells can be selected that show no off-target toxicity.
In conclusion, in this study, we demonstrated that TCR transfer results in neoreactive mixed TCR dimer formation. This formation of neoreactive mixed TCR dimers is not a feature of a specific TCR, because we observed this in all virus-specific T cells tested, with different introduced TCR α or β chains. We therefore underline the importance of facilitating matched pairing of introduced TCR chains, and diminishing the chance of formation of harmful neoreactive mixed TCR dimers by using T cell populations with restricted TCR repertoire as host cells for TCR transfer.
Materials and Methods
Retroviral Vector Construction and Production of Retroviral Supernatant. TCRAV and TCRBV gene use of the different Ag-specific T cell clones was determined as previously described (7) . All TCR AV and BV chains derived from different high-affinity mHAg-specific (HA-2 and HA-1) and virus-specific T cell clones (CMV) were cloned separately into the Moloney murine leukemia virus-based LZRS retroviral vector (described in detail in SI Materials and Methods). In addition, cysteine-modified HA-1.M7-TCR chains were constructed as previously described by introducing cysteine residues at positions 48 of the TCRα and position 57 of the TCRβ constant domains (16, 17) . TCR-AV chains were always combined via the IRES sequence with the marker eGFP, and the TCR-BV chains with the truncated nerve growth factor receptor (ΔNGF-R). The retroviral vectors used in Fig. 5B contained either the unmodified or cysteine-modified HA1.M7 TCR α and β chains linked with picornavirus-derived self-cleaving 2A sequence (T2A) (23) and were combined via the IRES sequence with the marker ΔNGF-R. Retroviral supernatant was generated using φ-NX-A as previously described (27) .
HLA Class I Tetrameric Complexes, Flow Cytometry Analyses, and Cell Sorting. PE-or APC-conjugated tetrameric complexes were constructed as previously described (28) , with minor modifications. The following tetrameric complexes were constructed: tetrameric HLA-A1 complexes in combination with CMVpp50 VTE (pp50) or CMV-pp65 YSE (pp65) peptide, and tetrameric HLA-B8 complexes in combination with CMV-IE-1 ELR (IE-1) or EBV-BZLF-1 RAK (BZLF-1). For flow cytometry analyses as well as flow cytometry-based sorting, cells were labeled with tetramers for 1 h at 4°C, and during the last 30 min mAbs directed against the various cell surface molecules were added. Sorting was performed at 4°C. mAbs used are described in SI Materials and Methods.
Cells. All studies were conducted with approval of the institutional review board at Leiden University Medical Center. After informed consent, virusspecific T cells were isolated from different healthy individuals (UKL, MBX, CVO, UGW.) using different virus-specific tetramers (>95% purity). Tetramer positive T cells were restimulated every 2 wk as described previously (13) and expanded. Retroviral transduction was performed as described previously (8) using recombinant human fibronectin fragments CH-296 (27) . TCR transduced (td) virus-specific T cells were sorted based on eGFP and ΔNGF-R positivity (>99% purity), and the cells were expanded in bulk. To analyze the reactivity of TCR td T cells, a panel of HLA typed EBV-transformed lymphoblastoid cell lines (LCLs) was used (Table S2 ). LCLs were maintained in Iscove's modified Dulbecco's medium supplemented with 10% FBS.
Analysis of Ag-Specific IFN-γ Production. TCR td virus-specific T cells were tested for IFN-γ production against the HLA typed LCL panel. To determine IFN-γ production, 5,000 T cells were cocultured with 20,000 LCLs; after overnight incubation, supernatant was harvested and tested in a standard ELISA (CLB). As positive control for the activity of the endogenous and introduced TCRs, the T cells were stimulated with LCLs pulsed for 1 h at 37°C with the different viral and mHag peptides at a final concentration of 1 μg/mL. To determine the HLA restriction molecules essential for recognition of the mixed TCR dimers, blocking studies were performed. Antibodies used are described in SI Materials and Methods.
TCR td virus-specific T cells were tested for IFN-γ production against normal human cell subsets; for this purpose, CD4 + , CD19 + , and CD14 + cell subsets were MACS isolated from PBMC as described in SI Materials and Methods. TCR td virus-specific T cells were tested against these different purified (>90%) CD4 + , CD19 + , and CD14 + cell subsets directly ex vivo and after in vitro activation of these cell subsets, as described in SI Materials and Methods.
Chromium Release Assay and CFSE-Based Cytotoxicity Assay. To test the capacity of T cells to specifically lyse Ag positive target cells, a standard 4-h chromium release assay using different effector-to-target ratios was performed as previously described (8) . Furthermore, to be able to analyze cytotoxicity after several days, we used a CFSE-based cytotoxicity assay (29) as described in SI Materials and Methods.
